logo BDSP

Base documentaire


  1. Thiazide diuretics and the initiation of anti-gout therapy.

    Article - En anglais

    While physiologic and epidemiologic evidence link diuretic therapy with hyperuricemia, no previous study has quantified the risk for initiation of treatment specific for hyperuricemia or gout among elderly patients taking thiazide diuretics.

    We performed a retrospective cohort study of 9249 enrollees aged 65 or older in the New Jersey Medicaid program who were newly started on an antihypertensive medication from November 1981 through February 1989 and who had no prior use of anti-gout therapy (allopurinol, colchicine, or a uricosuric) during the preceding one-year period.

    We used Cox proportional hazards analysis to determine the risk for the initiation of anti-gout therapy in patients using various antihypertensive treatment regimens relative to no antihypertensive exposure.

    Patient follow-up extended for up to two years.

    Antihypertensive exposure was characterized over the entire period of follow-up according to the following categories :

    • thiazide diuretic therapy alone ;

    • non-thiazide antihypertensive therapy ;

    • thiazide diuretic therapy in combination with any non-thiazide antihypertensive agent (s) ;

    • and no antihypertensive use.

    Antihypertensive exposure was entered into the model as a time-varying covariate.

    Estimates of risk were adjusted for age, sex, race, nursing home residence, number of prescriptions filled, intensity of physician use, hospitalization history, and year of antihypertensive treatment initiation. (...)

    Mots-clés Pascal : Hypertension artérielle, Thiazide, Antihypertenseur, Hypouricémiant, Goutte(pathologie), Epidémiologie, Chimiothérapie, Traitement, Toxicité, Homme, Etude cohorte, Urique acide, Etats Unis, Amérique du Nord, Amérique, Appareil circulatoire pathologie, Métabolisme pathologie, Hyperuricémie, Système ostéoarticulaire pathologie

    Mots-clés Pascal anglais : Hypertension, Thiazide, Antihypertensive agent, Hypouricemic agent, Gout, Epidemiology, Chemotherapy, Treatment, Toxicity, Human, Cohort study, Uric acid, United States, North America, America, Cardiovascular disease, Metabolic diseases, Hyperuricemia, Diseases of the osteoarticular system

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0202641

    Code Inist : 002B02U10. Création : 11/09/1998.